Thereafter, aberrant ALK, either as a fusion partner or a full-length protein with activating mutations or overexpression, has been reported in a wide range of human malignancies including non-small cell lung cancer (NSCLC) and neuroblastoma (NB) (2, 3). Here, ALK is linked to neuroblastoma.